AbbVie
Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug
Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease
AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics
AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition
FDA Approves Vyalev: A Breakthrough Continuous Infusion Therapy for Advanced Parkinson’s Disease
Vyalev, Parkinson’s disease, continuous infusion therapy, FDA approval, AbbVie, motor fluctuations, levodopa, carbidopa
AbbVie’s Tavapadon Shows Promising Results in Phase III Trial for Parkinson’s Disease
AbbVie, Tavapadon, Parkinson’s Disease, Phase III Trial, TEMPO-1, Cerevel Therapeutics
AstraZeneca Unveils In-House ADCs, Rivaling AbbVie and Pfizer’s Cancer Therapies
AstraZeneca, Daiichi Sankyo, Antibody-Drug Conjugates (ADCs), Cancer Therapies, AbbVie, Pfizer, Oncology, Biotechnology
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio
AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech
AbbVie’s Epkinly Enters Follicular Lymphoma Market, Competing with Roche’s Lunsumio
Epkinly, Lunsumio, follicular lymphoma, bispecific antibodies, AbbVie, Roche, FDA approval, cancer treatment
AbbVie’s Duopa Successor in Parkinson’s Rejected Again Due to Third-Party Manufacturer Issues
AbbVie, Duopa, Parkinson’s disease, FDA rejection, third-party manufacturer, ABBV-951, carbidopa, levodopa, subcutaneous pump device